Close

Forest Labs (FRX) Cuts FY13 Outlook Amid 'Evolving Conditions in the Lexapro/escitalopram Market

Go back to Forest Labs (FRX) Cuts FY13 Outlook Amid 'Evolving Conditions in the Lexapro/escitalopram Market